<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338712</url>
  </required_header>
  <id_info>
    <org_study_id>mi-RNA-PCa</org_study_id>
    <nct_id>NCT03338712</nct_id>
  </id_info>
  <brief_title>Micro-RNA Expression Profiles in Localised Prostate Cancer</brief_title>
  <official_title>Micro-RNA Expression Profiles in Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrence free survival The patients will be followed in regular time intervals in
      accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the
      German Urological Association. Data will be updated once yearly for until death.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigators no longer in business
  </why_stopped>
  <start_date type="Anticipated">February 1, 2010</start_date>
  <completion_date type="Anticipated">April 1, 2016</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>Up to 120 months. From date of inclusion until date of death from any cause</time_frame>
    <description>The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>Up to 120 months. From date of inclusion until date of death from any cause</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Radical Prostatectomy</condition>
  <eligibility>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35 Years to 80 Years

          -  Male

          -  Patients with clinically localised high risk prostate cancer

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

